Automotive and Transportation Leader Pamela Fletcher Joins Sion Power as Chief Executive Officer
Sion Power Corporation, a leading technology developer of next-generation batteries for electric vehicles (EV), announced today that Pamela Fletcher has joined the company as its new Chief Executive Officer. A renowned veteran of the automotive industry, Fletcher brings a proven track record of electric vehicle development and deployment, which she will leverage to accelerate the company’s transition to commercialization. She succeeds Tracy Kelley, who will transition to President and Chief Science Officer of Sion Power and continue development of world class battery technology breakthroughs.
Most recently, Fletcher served as the Senior Vice President, Chief Sustainability Officer, at Delta Air Lines where she led the airline’s sustainability and innovation efforts in service of the company’s Net Zero future. In this role she set a strategy to net zero emissions by 2050 and activated initiatives across the organization to achieve short to long-term goals, an industry first. Before her tenure at Delta Air Lines, Fletcher spent more than 15 years at General Motors where she held instrumental leadership positions, including Vice President of Global Innovation and Vice President of Electric Vehicles. She led the teams that delivered the electric Chevrolet Bolt and Chevrolet Volt to market, as well as the first true, hands-free driver assistance technology—Super Cruise.
“Again and again, Pam has been at the forefront of the automotive industry, leading award-winning product, technology, and new businesses teams. She has a passion for innovation and a track record of scaling high-growth business ventures, disrupting established industries, and attracting new customers. She has the skillset and passion to lead the commercialization of Sion Power’s breakthrough Licerion® battery technology and we’re thrilled for this next chapter,” said Stefan Jacoby, Chair, Sion Board of Directors.
“Sion Power is poised to be the first company to commercialize a lithium-metal anode through its Licerion® technology for large volume EV applications, thus disrupting the global battery industry,” said Fletcher, CEO, Sion Power. “Commercialization means more affordable electric vehicles for consumers more quickly, bolstering adoption and ultimately helping us get closer to a zero emissions world. I am honored to join this incredible company and I want to thank Tracy Kelley for his leadership to this pivotal point and all he will continue to do for our team.”
Sion Power has developed lithium-based batteries for over three decades. Over the past eight years, batteries based on their proprietary and patented technology have been its focus. This disruptive energy storage system is projected to deliver twice the specific energy when compared to today's conventional lithium-ion batteries. To learn more, visit sionpower.com.
About Sion Power
Sion Power is moving the rechargeable battery industry forward with its Licerion® technology. Licerion® is an advanced approach to lithium-metal batteries containing twice the energy in the same size and weight battery, compared to a traditional lithium-ion battery. At up to 500 Wh/kg, Licerion® batteries are produced at scale in large-format cells. As a result, Licerion® batteries have the potential to significantly enhance the performance of commercial and consumer electric vehicles. Visit Sion Power at sionpower.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813464461/en/
Contacts
Press.Release@sionpower.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom